<DOC>
	<DOC>NCT02745860</DOC>
	<brief_summary>Clinical study in healthy adult subjects to compare the adult tablet of selexipag with the tablet developed for children.</brief_summary>
	<brief_title>Comparison of Two Dose Strengths of Selexipag in Healthy Adults</brief_title>
	<detailed_description>Healthy male adults receive a single dose of selexipag (200 µg) but using a different tablet strength (4 film-coated pediatric tablets of 50 µg versus one film-coated tablet of 200 µg selexipag) during each of the two study periods. There is a washout of 7-9 days between the two study treatment administrations.</detailed_description>
	<mesh_term>Selexipag</mesh_term>
	<criteria>Key inclusion Criteria: Male subjects aged from 18 to 45 years (inclusive) at screening Signed informed consent form Body mass index (BMI) between 18.0 and 28.0 kg/m2 (inclusive) at screening Healthy on the basis of physical examination,cardiovascular assessments and laboratory tests Key exclusion Criteria: Any contraindication to the study treatments History or clinical evidence of any disease or medical / surgical condition or treatment, which may put the subject at risk of participation in the study or may interfere with the absorption, distribution, metabolism or excretion of the study treatments Any circumstances or conditions, which, in the opinion of the investigator, may affect the subject's full participation in the study or compliance with the protocol</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>selexipag</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>